[Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].
Bello
P
P
Comité de Procedimientos de la SEMN, España.
Almoguera
M I
MI
Pajares
M
M
Olivas
C
C
Lapeña
L
L
Freire
J M
JM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000528:radiation effects; D000075202:Contraindications; D004334:Drug Administration Schedule; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007258:Informed Consent; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D008487:Medical History Taking; D016499:Radioimmunotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D018796:Immunoconjugates; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan